MedTrace Logo

Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors

NCT01851200 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2018-02-07

No results posted yet for this study

Summary

The purpose of the study is to assess the activity of Brentuximab vedotin in refractory germ cell tumors.

Conditions

  • Germ Cell Cancer

Interventions

DRUG

Brentuximab Vedotin

Intravenous Brentuximab Vedotin at the dose of 1.8 mg/Kg every 3 weeks until disease progression or onset of unacceptable toxicity

Sponsors & Collaborators

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

    collaborator OTHER

  • Millennium Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Fondazione Michelangelo

    lead OTHER

Principal Investigators

  • Alessandro M Gianni, MD · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

  • Roberto Salvioni, MD · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

  • Andrea Necchi, MD · Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2017-08-31
Completion
2017-09-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01851200 on ClinicalTrials.gov